Amarin (AMRN) Shares Down 0%

Amarin Co. plc (NASDAQ:AMRN) dropped 0% on Monday . The stock traded as low as $3.99 and last traded at $4.01. Approximately 3,253,551 shares traded hands during mid-day trading, an increase of 42% from the average daily volume of 2,283,366 shares. The stock had previously closed at $4.01.

AMRN has been the subject of several research analyst reports. Cantor Fitzgerald set a $10.00 price objective on Amarin and gave the company a “buy” rating in a report on Tuesday, December 19th. Zacks Investment Research downgraded Amarin from a “buy” rating to a “hold” rating in a report on Friday, November 3rd. Jefferies Group reissued a “buy” rating on shares of Amarin in a report on Wednesday, October 11th. BidaskClub raised Amarin from a “sell” rating to a “hold” rating in a report on Thursday, December 21st. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Amarin in a report on Thursday, November 2nd. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Amarin presently has a consensus rating of “Buy” and an average price target of $7.75.

The company has a debt-to-equity ratio of -1.48, a current ratio of 1.63 and a quick ratio of 1.32. The stock has a market cap of $1,090.00, a price-to-earnings ratio of -14.85 and a beta of 0.62.

Amarin (NASDAQ:AMRN) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The company had revenue of $47.10 million for the quarter, compared to analyst estimates of $45.85 million. During the same period in the prior year, the business earned ($0.08) earnings per share. Amarin’s revenue for the quarter was up 45.4% compared to the same quarter last year. equities analysts anticipate that Amarin Co. plc will post -0.22 EPS for the current fiscal year.

In other Amarin news, insider John F. Thero acquired 10,000 shares of the business’s stock in a transaction on Thursday, November 30th. The stock was purchased at an average price of $3.24 per share, for a total transaction of $32,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel Joseph T. Kennedy sold 51,106 shares of the stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $4.10, for a total value of $209,534.60. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 381,863 shares of company stock valued at $1,646,979. Corporate insiders own 3.72% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in AMRN. JPMorgan Chase & Co. raised its position in Amarin by 681.5% in the second quarter. JPMorgan Chase & Co. now owns 278,134 shares of the biopharmaceutical company’s stock worth $1,121,000 after acquiring an additional 242,544 shares in the last quarter. Wells Fargo & Company MN raised its position in Amarin by 15.2% in the second quarter. Wells Fargo & Company MN now owns 37,801 shares of the biopharmaceutical company’s stock worth $152,000 after acquiring an additional 5,000 shares in the last quarter. OxFORD Asset Management LLP raised its position in Amarin by 114.2% in the second quarter. OxFORD Asset Management LLP now owns 135,773 shares of the biopharmaceutical company’s stock worth $547,000 after acquiring an additional 72,390 shares in the last quarter. Intrinsic Edge Capital Management LLC purchased a new position in Amarin in the second quarter worth $725,000. Finally, State Street Corp raised its position in Amarin by 1.3% in the second quarter. State Street Corp now owns 201,995 shares of the biopharmaceutical company’s stock worth $814,000 after acquiring an additional 2,640 shares in the last quarter. Hedge funds and other institutional investors own 40.14% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://www.com-unik.info/2018/01/29/amarin-amrn-shares-down-0.html.

About Amarin

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit